ESTRO 2021 Abstract Book

S303

ESTRO 2021

Fig 2 - Mean scores of C15 domains, comparing responders (red) and non-responders (blue). Higher scores indicate better functioning. In green the available age-matched reference population without a history of bone metastases is depicted.

Conclusion Patients responding to palliative radiotherapy for pain have better QoL compared to non-responding patients, independently of other confounding factors. As the improvements in QoL are small, further analysis of potential associations between clinical pain response and patient reported outcomes is needed to maintain or even improve QoL in patients with bone metastases. OC-0408 Higher-dose radiotherapy for metastatic spinal cord compression: First results of a phase II trial D. Rades 1 , C. Staackmann 1 , D. Lomidze 2 , D. Lomidze 3 , N. Jankarashvili 4 , A. Navarro 5 , F. Lopez 6 , B. Šegedin 7,8 , B. Groselj 7,8 , A.J. Conde-Moreno 9 , N.H. Holländer 10 , S.E. Schild 11 , J. Cacicedo 12 1 University of Lübeck, Radiation Oncology, Lübeck, Germany; 2 Tbilisi State Medical University , Radiation Oncology, Tbilisi, Georgia; 3 Ingorokva High Medical Technology University Clinic, Radiation Oncology, Tbilisi, Georgia; 4 Acad. F. Todua Medical Center - Research Institute of Clinical Medicine, Radiation Oncology, Tbilisi, Georgia; 5 Catalan Institute of Oncology, Radiation Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 6 University Hospital Ramón y Cajal, Radiation Oncology, Madrid, Spain; 7 Institute of Oncology Ljubljana , Radiotherapy, Ljubljana, Slovenia; 8 Faculty of Medicine, University of Ljubljana, Radiotherapy, Ljubljana, Slovenia; 9 University and Polytechnic Hospital La Fe, Radiation Oncology, Valencia, Spain; 10 Zealand University Hospital, Oncology and Palliative Units, Naestved, Denmark; 11 Mayo Clinic, Radiation Oncology, Scottsdale, AZ, USA; 12 Cruces University Hospital/Biocruces Health Research Institute, Radiation Oncology, Barakaldo, Spain Purpose or Objective To evaluate the outcomes after high-precison RT (preferably VMAT) with increased doses (EQD2 for tumors >40 Gy) when compared to 10x3 Gy (EQD2=32.5 Gy) for metastatic spinal cord compression (MSCC) in patients with favorable survival prognoses.